+
+
Stay Informed

SURGICAL VALVE SOLUTIONS

The Abbott portfolio of surgical valves includes stented tissue valves, mechanical valves, and annuloplasty rings that are designed to rebuild healthier hearts.

SURGICAL VALVE SOLUTIONS

The Abbott portfolio of surgical valves includes stented tissue valves, mechanical valves, and annuloplasty rings that are designed to rebuild healthier hearts.

EPIC™ MAX

SURGICAL REPLACEMENT
AORTIC VALVE

Epic™ Max is designed to refine the future of aortic valve replacement lifetime management by providing unparalleled hemodynamics* while maintaining the Epic Platform’s ease of implant, proven durability, and features designed for future intervention.

Learn more about Epic MAX

*Compared to previous Epic Platform iterations.

EPIC™ PLUS

SURGICAL REPLACEMENT
MITRAL & AORTIC VALVE

The Epic™ Plus mitral and aortic valves feature Linx™ anticalcification technology* and provide the same trusted durability and performance—plus significant improvements to radiopacity and implantability to enable future interventions. The future-forward design gives you and your patients more choices when it comes to preserving long-term treatment paths.

Learn more about Epic Plus

*There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in humans.

EPIC™ PLUS

SURGICAL REPLACEMENT
MITRAL & AORTIC VALVE

The Epic™ Plus mitral and aortic valves feature Linx™ anticalcification technology* and provide the same trusted durability and performance—plus significant improvements to radiopacity and implantability to enable future interventions. The future-forward design gives you and your patients more choices when it comes to preserving long-term treatment paths.

Learn more about Epic Plus

*There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in humans.

REGENT™

SURGICAL REPLACEMENT
AORTIC VALVE

The Regent aortic mechanical heart valve delivers exceptional hemodynamics and clinical performance with a proven long-term legacy of structural integrity and durability. Abbott mechanical heart valves lead the way with a proven bileaflet design that results in low thrombogenicity and excellent patient outcomes.

Learn more about Regent

MASTERS SERIES

SURGICAL REPLACEMENT
AORTIC & MITRAL VALVE

The Masters Series aortic and mitral mechanical heart valves are rotatable, bileaflet valves designed for secure implantation. The portfolio includes an expansive range of sizes to help you make the best decisions for your patients. Unique design features have established Abbott mechanical heart valves as a gold standard for reliability and performance.

Learn more about Masters Series

MASTERS SERIES

SURGICAL REPLACEMENT
AORTIC & MITRAL VALVE

The Masters Series aortic and mitral mechanical heart valves are rotatable, bileaflet valves designed for secure implantation. The portfolio includes an expansive range of sizes to help you make the best decisions for your patients. Unique design features have established Abbott mechanical heart valves as a gold standard for reliability and performance.

Learn more about Masters Series

Abbott mitral valve surgical repair solutions

MITRAL VALVE REPAIR SOLUTIONS

SURGICAL REPAIR
MITRAL VALVE

Abbott offers a comprehensive portfolio of mitral valve repair products from a single source. These customizable repair products are suitable for implant using open sternotomy and minimally invasive approaches such as robotic surgery.

Learn more about Repair Solutions

MAT-2114940 v3.0 | Item approved for U.S. use only.

Important Safety Information
  • Epic Max
  • Epic Plus
  • Regent
  • Master Series
  • TAILOR RING/BAND
  • ATTUNE™ RING
  • SÉGUIN RING
  • RIGID SADDLE RING

  • Rx Only

    EPIC™ MAX STENTED PORCINE TISSUE VALVES
    INDICATIONS FOR USE

    The Epic™ Max valve is indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic heart valve. It may also be used as a replacement for a previously implanted aortic prosthetic heart valve. 

    CONTRAINDICATIONS

    None known. 

    POTENTIAL ADVERSE EVENTS

    Adverse events potentially associated with the use of bioprosthetic heart valves (in alphabetical order) include: angina; cardiac arrhythmias; endocarditis; heart failure; hemolysis; hemolytic anemia; hemorrhage, anticoagulant/antiplatelet-related; leak, transvalvular or paravalvular; myocardial infarction; nonstructural dysfunction (entrapment by pannus or suture, inappropriate sizing or positioning, or other); prosthesis regurgitation; stroke; structural deterioration (calcification, leaflet tear, or other); thromboembolism; valve thrombosis. It is possible that these complications could lead to: reoperation; explantation; permanent disability; death. 

  • Rx Only

    EPIC™ PLUS/EPIC™ PLUS SUPRA STENTED PORCINE TISSUE VALVES

    INDICATION FOR USE

    The Epic™ Plus valve is indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic and/or mitral heart valve. It may also be used as a replacement for a previously implanted aortic and/or mitral prosthetic heart valve.

    The Epic™ Plus Supra valve is indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic heart valve. It may also be used as a replacement for a previously implanted aortic prosthetic heart valve.

    CONTRAINDICATIONS

    None known.

    POTENTIAL ADVERSE EVENTS

    Adverse events potentially associated with the use of bioprosthetic heart valves (in alphabetical order) include: angina; cardiac arrhythmias; endocarditis; heart failure; hemolysis; hemolytic anemia; hemorrhage, anticoagulant/antiplatelet-related; leak, transvalvular or paravalvular; myocardial infarction; nonstructural dysfunction (entrapment by pannus or suture, inappropriate sizing or positioning, or other); prosthesis regurgitation; stroke; structural deterioration (calcification, leaflet tear, or other); thromboembolism; valve thrombosis.

    It is possible that these complications could lead to: reoperation; explantation; permanent disability; death.

  • Rx Only

    REGENT™ MECHANICAL HEART VALVE

    INDICATION FOR USE

    The SJM Regent™ Mechanical Heart Valve is intended for use as a replacement valve in patients with a diseased, damaged, or malfunctioning aortic valve. This device may also be used to replace a previously implanted aortic prosthetic valve.

    CONTRAINDICATIONS

    The SJM Regent™ Mechanical Heart Valve is contraindicated for individuals unable to tolerate anticoagulation therapy.

    POTENTIAL ADVERSE EVENTS

    Complications are associated with replacement mechanical heart valves include, but are not limited to, hemolysis, infections, thrombus, or thromboembolism, valve dehiscence, unacceptable hemodynamic performance, hemorrhagic complications secondary to anticoagulation therapy, prosthetic failure, heart failure or death. Any of these complications may require reoperation or explantation of the device.

  • Rx Only

    MASTERS SERIES MECHANICAL HEART VALVE

    INDICATION FOR USE

    The SJM™ Masters Series Mechanical Heart Valve is intended for use as a replacement valve in patients with a diseased, damaged, or malfunctioning aortic or mitral heart valve. This device may also be used to replace a previously implanted mitral or aortic prosthetic valve.

    CONTRAINDICATIONS

    The SJM™ Masters Series Mechanical Heart Valve is contraindicated for individuals unable to tolerate anticoagulation therapy.

    POTENTIAL ADVERSE EVENTS

    Complications associated with replacement mechanical heart valves include, but are not limited to, hemolysis, infections, thrombus, or thromboembolism, valve dehiscence, unacceptable hemodynamic performance, hemorrhagic complications secondary to anticoagulation therapy, prosthetic failure, failure or death. Any of these complications may require reoperation or explantation of the device.

  • SJM TAILOR™ ANNULOPLASTY RING OR
    SJM TAILOR™ ANNULOPLASTY BAND

    INDICATIONS

    The ring/band is indicated for use in the repair of a mitral or tricuspid valve that is diseased or damaged due to acquired or congenital valvular disease. It is the responsibility of the surgeon to determine that the valve is repairable. The decision to undertake annuloplasty can be made only after visual analysis of the valve pathology. Only surgeons who have received appropriate training should perform valve repair using the ring/band.

    CONTRAINDICATIONS

    Use of the ring/band is contraindicated in cases where severe organic lesions with retracted chordae tendineae require valvular replacement, and where there are congenital malformations which lack valvular tissue. Additionally, use of the ring/band is contraindicated whenever the physician determines that the remaining functional valve tissue and valve support structures are not adequate to provide the required hemodynamic performance or structural strength. Use of the ring/band is contraindicated for active bacterial endocarditis.

    PRECAUTIONS

    • Sizers and accessories are supplied non-sterile, and must be cleaned and sterilized prior to each use.
    • Do not use cracked, crazed, deformed, or damaged sizer set components.
    • Do not bend sizers beyond a 90° angle.
    • Prior to using the sizers in the SJM Tailor™ & Attune™ ring robotic sizer set model TAR-510R, secure a suture to the sizer using the safety suture hole (see Figure 2). The suture should be long enough to remain outside the patient at all times the sizer is inside the patient. In the event that the sizer is dropped inside the patient, the safety suture can be used to retrieve the sizer.
    • Do not use a ring/band if the “USE BY” date on the packaging has passed.
    • The contents of the tray in which the ring/band is supplied have been sterilized. Ensure the tray is unopened and unbroken. If you note any damage, do not use the device, and contact St. Jude Medical™ Customer Service.
    • Remove the identification tag and suture prior to implantation. Avoid cutting or tearing the ring/ band during removal of the identification tag and suture.
    • Do not place sutures in the circumflex coronary artery or in the right coronary artery.
    • Do not place sutures in the atrial tissue, as this may result in impairment of the cardiac conduction system.
    • After selecting the appropriate size ring, should the surgeon elect to convert the ring to a C-band, the ring must be cut within the designated cut area. The cut area is identified by the two notched windows on the ring holder just inside the trigone indicator tabs. Once the ring has been cut, remove the cut segment prior to implantation of the ring.
    • After the ring has been cut and the cut segment removed, care should be taken to remove any loose suture within the cut area prior to implantation of the ring.
    • To avoid damage to the fabric covering the ring/ band, cutting edge needles should not be used, and manipulation with forceps should be avoided during implantation.
    • If an implant suture inadvertently pierces a ring/ band retaining loop, the holder may not release from the ring/band. To facilitate release, cut the retaining loop suture close to the implant suture.
    • Remove any loose suture or thread, which may be a source of thrombus or thromboembolism.
    • Prophylactic antibiotic treatment should be
    • considered for all patients undergoing dental or other potentially bacteremic procedures.
       

    POTENTIAL ADVERSE EVENTS

    As with prosthetic heart valves, serious complications may be associated with the use of this device, sometimes leading to death. Complications necessitating reoperation may occur at varying intervals and include: thrombus; hemolysis; left ventricular outflow tract obstruction; systolic anterior motion; damage to coronary arteries; stenosis; uncorrected or recurrent regurgitation; partial or complete dislodgment of the ring/band from its site of attachment; thromboembolism; A-V block; endocarditis; low cardiac output; and bleeding disorders relating to the use of anticoagulant therapy.

  • ATTUNE™ FLEXIBLE ADJUSTABLE
    ANNULOPLASTY RING

    INDICATIONS

    The Attune™ Flexible Adjustable Annuloplasty Ring is indicated for use in the repair of a mitral or tricuspid valve that is diseased or damaged due to acquired or congenital valvular disease. It is the responsibility of the surgeon to determine that the valve is repairable and does not require replacement. The decision to undertake annuloplasty can be made only after visual analysis of the valve pathology. Only surgeons who have received appropriate training should perform valve repair using an Attune™ Ring.

    CONTRAINDICATIONS

    Use of the Attune™ Flexible Adjustable Annuloplasty Ring is contraindicated in cases where severe organic lesions with retracted chordae tendineae require valvular replacement, and where there are congenital malformations which lack valvular tissue. Additionally, use of the Attune™ Ring is contraindicated whenever the physician determines that the remaining functional valve tissue and valve support structures are not adequate to provide the required hemodynamic performance or structural strength. Use of the Attune™ Ring is contraindicated for active bacterial endocarditis.

    PRECAUTIONS

    • Do not use an Attune™ Flexible Adjustable
    • Annuloplasty Ring if the “USE BY” date on the packaging has passed.
    • Examine the device packaging carefully, and ensure the tray is unopened and unbroken. If you note any damage, do not use the device, and contact St. Jude Medical™ Customer Service.
    • Sizers are supplied non-sterile and must be cleaned and sterilized prior to each use.
    • Do not used cracked, crazed, corroded, deformed, damaged, or degraded sizer set components.
    • Prior to using the sizers in the SJM Tailor™ & Attune™ Ring Robotic Sizer Set models TAR-510R or
    • TAR-505R, secure a suture to the sizer using the safety suture hole. The suture should be long enough to remain outside the patient at all times the sizer is inside the patient. In the event that the sizer is dropped inside the patient, the safety suture can be used to retrieve the sizer.
    • Remove the Attune™ Ring from the support prior to implantation.
    • Remove the identification tag and suture prior to implantation. Avoid cutting or tearing the Attune™ Ring when removing the identification tag and suture.
    • Do not cut the Attune™ Ring.
    • To avoid damage to the Attune™ Ring, do not us cutting edge needles, and exercise care when holding or manipulating the Attune™ Ring with forceps.
    • Implantation of the Attune™ Ring has not been evaluated with the use of nitinol clips.
    • Do not place suture(s) through the posterior portion of the Attune™ Ring prior to finalizing and securing the adjustment, as this may result in disabling the adjustment suture.
    • Do not place sutures in the circumflex coronary artery or in the right coronary artery.
    • Do not place sutures in the atrial tissue, as this may result in impairment of the cardiac conduction system. Remove any loose suture or thread, which may be a source of thrombus or thromboembolism.
    • Prophylactic antibiotic treatment should be considered for all patients undergoing dental procedures.

    POTENTIAL ADVERSE EVENTS

    As with prosthetic heart valves, serious complications may be associated with the use of this device, sometimes leading to death. Complications necessitating reoperation may occur at varying intervals and include: thrombus; hemolysis; left ventricular outflow tract obstruction; systolic anterior motion; damage to coronary arteries; stenosis; uncorrected or recurrent regurgitation; partial or complete dislodgment of the Attune™ Ring from its site of attachment; thromboembolism; A-V block; endocarditis; low cardiac output; and bleeding disorders relating to the use of anticoagulant therapy.

  • SJM™ SÉGUIN ANNULOPLASTY RING / SJM™ SÉGUIN
    ANNULOPLASTY RING SIZER SET MODEL SAR-501

    INDICATIONS

    The SJM™ Séguin Annuloplasty Ring is indicated for use in the repair of mitral valves that are diseased or damaged due to acquired or congenital processes. It is the responsibility of the surgeon to determine that the valve is repairable and does not require replacement. The decision to undertake annuloplasty can be made only after visual analysis of the valve pathology. Only surgeons who have received appropriate training should perform valve repair using the SJM™ Séguin Annuloplasty Ring. The SJM™ Séguin Annuloplasty Ring Sizer Set Model SAR-501 is indicated for use with the SJM™ Séguin Annuloplasty Ring.

    CONTRAINDICATIONS

    Use of the SJM™ Séguin Annuloplasty Ring is contraindicated in cases where severe organic lesions with retracted chordae tendineae require valvular replacement and where there are congenital malformations which lack valvular tissue. Additionally, use of the ring is contraindicated whenever the physician determines that the remaining functional valve tissue and valve support structures are not adequate to provide the required hemodynamic performance or structural strength. Use of the SJM™ Séguin Annuloplasty Ring is contraindicated for active bacterial endocarditis. Use of the SJM™ Séguin Annuloplasty Ring Sizer Set Model SAR-501 with products other than the SJM™ Séguin Annuloplasty Ring is contraindicated. When sterilizing the SAR-501 sizer set, any sterilization method other than steam is contraindicated.

    PRECAUTIONS

    • SJM™ Séguin Annuloplasty Ring
    • Do not use the ring if the “USE BY” date on the packaging has passed.
    • Examine the device packaging carefully, and ensure the pouch is unopened and unbroken. If you note any damage, do not use the device, and contact St. Jude Medical™ customer service.
    • Remove the identification tag and suture prior to implantation. Avoid cutting or tearing the ring during removal of the identification tag and suture.
    • Do not place sutures in the circumflex coronary artery or in the right coronary artery.
    • Do not place sutures in the atrial tissue, as this may result in impairment of the cardiac conduction system.
    • Do not attempt to deform or otherwise alter the configuration of the prosthetic ring to conform to a specific annular anatomy, as this could damage the ring. If the ring is not suitably sized for the annulus, a larger or smaller ring should be chosen.
    • To avoid damage to the fabric covering the ring, do not use cutting edge needles, and avoid manipulation with forceps during implantation.
    • Remove any loose suture or thread, which may be a source of thrombus or thromboembolism.
    • Prophylactic antibiotic treatment should be considered for all patients undergoing dental or other potentially bacteremic procedures.
    • SJM™ Séguin Annuloplasty Ring Sizer Set
    • Model SAR-501
    • All sizer set components are supplied non-sterile, and must be cleaned and steam sterilized prior to each use.
    • The sterilization temperature must not exceed 138°C (280°F).
    • The autoclavable tray and cover do not provide a sterile barrier.
    • Do not use cracked, deformed, or damaged sizer set components.
    • Do not bend handles beyond a 90° angle.
    • Do not expose sizer set components to cleaning or rinse agents that are not compatible with polysulfone or polyphenylsulfone.

    POTENTIAL ADVERSE EVENTS

    As with prosthetic heart valves, serious complications may be associated with the use of this device, sometimes leading to death. Complications necessitating re-operation may occur at varying intervals and include: thrombus; hemolysis; ring fracture; left ventricular outflow tract obstruction; systolic anterior motion; damage to coronary arteries; stenosis; uncorrected or recurrent regurgitation; partial or complete dislodgment of the ring from its site of attachment; thromboembolism; A-V block; endocarditis; low cardiac output; and bleeding disorders relating to the use of anticoagulant therapy.

  • SJM™ RIGID SADDLE RING
    INDICATION FOR USE

    The SJM™ Rigid Saddle Ring is indicated for use to correct annular dilation, increase leaflet coaptation, and prevent further dilation of the mitral valve annulus caused by disease states such as degenerative disease, rheumatic disease, ischemia, or vascular disease. The combination of prosthetic ring with valvuloplasty may be used in all acquired or congenital mitral insufficiencies with dilation and deformation of the fibrous mitral annulus. For mitral insufficiencies with no subvalvular lesions and normal valvular movements, prosthetic ring implant alone may be sufficient. However, annuloplasty ring implant along with mitral valvuloplasty repair must be considered for insufficiencies with a prolapsed valve due to elongation or rupture of the chordae tendineae and for insufficiencies with limitation of valvular movements due to fusion of the commissures or chordae tendineae, or chordal hypertrophy.

    CONTRAINDICATIONS

    Use of the SJM™ Rigid Saddle Ring is contraindicated in cases where severe organic lesions with retracted chordae tendineae require valvular replacement and where there are congenital malformations which lack valvular tissue. Additionally, use of the ring is contraindicated whenever the physician determines that the remaining functional valve tissue and valve support structures are not adequate to provide the required hemodynamic performance or structural strength. Use of the SJM Rigid Saddle Ring is contraindicated for active bacterial endocarditis.

    SUMMARY OF PRECAUTIONS

    • Do not use a ring if the “USE BEFORE” date on the packaging has passed.
    • The contents of the tray in which the ring is supplied have been sterilized. Ensure the tray
    • and the seal are unopened and unbroken.
    • Remove the serial number tag and suture prior to implantation. Exercise care to avoid cutting or tearing the ring during removal of the identification tag.
    • Do not place sutures in the circumflex coronary artery or in the right coronary artery.
    • Sutures should not be placed in any atrial tissue, as impairment of cardiac conduction may occur.
    • Sizers are supplied non-sterile, and must be cleaned and sterilized prior to each use. Do not use cracked or deformed sizers.
    • To avoid damage to the fabric covering the ring, cutting edge needles should not be used and manipulation with sharp-toothed metal forceps should be avoided during implantation.
    • If an implant suture inadvertently pierces a ring retaining loop, the holder may not release from the ring. To facilitate release, cut the retaining loop suture close to the implant suture.
    • Take care to remove any loose suture or thread, which may be a source of thrombus or thromboembolism.
    • Do not alter or deform ring to conform to the anatomy.
    • Prophylactic antibiotic treatment should be considered for all patients undergoing dental or other potentially bacteremic procedures.

    SURGICAL CONSIDERATIONS

    • Suture techniques may vary according to the preferences of the implanting surgeon and the needs of the patient. Please consult the references listed in this manual for further informatio regarding surgical options for mitral valve repair. 1,2,3
    • To avoid distortion of the patient’s annulus, it is important to maintain even suture spacing within the annular tissue.
    • It is imperative to retain correct positioning of the leaflets relative to the SJM Rigid Saddle Ring. The SJM Rigid Saddle Ring commissure markers and posterior marker should be used as reference points for reconstruction of the annulus.
    • To securely anchor the sutures in the sewing cuff, place the sutures slightly outside of the running green suture marker. Sutures anchoring the ring must be placed so as to engage the fibrous tissue that connects the base of the leaflet, the atrium, and the orifice of the ventricle.
    • To ensure adequate distribution of suture stresses in patients with cardiomyopathy, numeroussutures should be used to secure the ring.1
    • Intraoperative echocardiography is recommended to assess valvular competency and quality of mitral repair.
    • Once all sutures have been placed on the cuff, the ring may be parachuted down into the annulus. If desired, the ring holder may be used to maintain the shape of the ring while the sutures are tied off. To facilitate ty-ing, the handle may be removed from the ring holder by using a forceps to depress the release button. Once all of the sutures have been tied, the handle may be reattached to the holder to facilitate removal. To remove the ring holder, cut the retaining suture.
    • After the ring has been implanted, depress the release button to remove the ring delivery system. The ring holder should be discarded.
    • CAUTION: To avoid damage to the fabric covering the ring, cutting edge needles and sharp-toothed forceps should not be used during implantation.
    • CAUTION: If an implant suture inadvertently pierces a ring retaining loop, the holder may not release from the ring. To facilitate release, cut the retaining loop suture close to the implant suture. Take care to remove any loose material.

    POTENTIAL SIDE EFFECTS

    As with prosthetic heart valves, serious complications may be associated with the use of this device, sometimes leading to death. Complications necessitating reoperation may occur at varying intervals and include: thrombus hemolysis; ring fracture; left ventricular outflow tract obstruction; systolic anterior motion; damage to coronary arteries; stenosis; uncorrected or recurrent regurgitation; partial or complete dislodgment of the ring from its site of attachment; thromboembolism; A-V block; endocarditis; low cardiac output; and bleeding disorders relating to the use of anticoagulant therapy.

    1. Romano, Mathew A. and Bolling, Steven F., Mitral Valve Repair as an Alternative Treatment for Heart Failure Patients. Heart Failure Monitor, 4(1): 7-12, 2003.
    2. Carpentier, A., Mitral Valve Reconstructive Surgery. Operative Surgery, 3rd Edition. Butterworths Publishers, 169-177, 1977.
    3. Carpentier, A. Cardiac Valve Surgery-The French Correction. J. Thorac. Cardiovasc. Surg., 86:323-377, 1983.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. VISITOR INTERNATIONAL VISITOR

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+